Holen Sie sich die Stockscreener-App
7.20
4.00%
-0.30
Handel nachbörslich:
7.20
Schlusskurs vom Vortag:
$7.50
Offen:
$7.5
24-Stunden-Volumen:
2.03M
Relative Volume:
0.70
Marktkapitalisierung:
$525.53M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-1.5418
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+10.60%
1M Leistung:
-23.16%
6M Leistung:
-73.05%
1J Leistung:
-77.67%
1-Tages-Spanne:
$6.95
$7.50
1-Wochen-Bereich:
$6.48
$7.60
52-Wochen-Spanne:
$5.90
$34.11
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.20 | 475.17M | 161.10M | -308.60M | -259.90M | -4.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Arvinas (ARVN) Faces Downgrade Amid Clinical Trial Results | ARV - GuruFocus
Arvinas (ARVN) Announces Promising Phase 3 Trial Results for Vepdegestrant | ARVN Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Pfizer-Arvinas breast cancer drug tops AstraZeneca’s in delaying progression - WTVB
Arvinas (NASDAQ:ARVN) Shares Down 4.7%What's Next? - MarketBeat
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters
Pfizer and Arvinas Plan FDA Submission for Breast Cancer Drug - GuruFocus
Pfizer, Arvinas report positive breast cancer drug trial - breakingthenews.net
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2 - Seeking Alpha
(ARVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Voloridge Investment Management LLC Makes New Investment in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer - marketscreener.com
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progre - GuruFocus
Is Trump Media Stock a Buy After $2.5 Billion Bitcoin Treasury Deal? - The Globe and Mail
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? - MSN
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer - BioPharma Dive
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer - GlobeNewswire
#ASCO25: Arvinas, Pfizer’s PROTAC in breast cancer no better than oral SERDs - Endpoints News
Here Are My Top 3 High-Yield Pipeline Stocks to Buy Now - The Globe and Mail
3 Dividend Stocks to Buy With $500 and Hold Forever - The Globe and Mail
Arvinas (NASDAQ:ARVN) Trading Up 7.9%Still a Buy? - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Arvinas to Present at Jefferies Global Healthcare Conference | ARVN Stock News - GuruFocus
Protein Degradation Pioneer Arvinas Reveals Latest Progress at Major Jefferies Healthcare Conference - Stock Titan
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Two Sigma Advisers LP - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm - Yahoo Finance
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) - Business Wire
Prediction: 2 AI Stocks Will Be Worth More Than Apple Stock Before the End of 2026 - The Globe and Mail
3 Top High-Yield Dividend Stocks to Buy and Hold Through at Least the End of the Decade - The Globe and Mail
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks By Investing.com - Investing.com South Africa
Woodline Partners LP Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks - Investing.com
Twinbeech Capital LP Acquires New Stake in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Buys 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
BNP Paribas Financial Markets Purchases 7,243 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and Encourages Investors to Contact the Firm - TradingView
RTW Investments LP Raises Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
(ARVN) Proactive Strategies - news.stocktradersdaily.com
Patient Square Capital LP Acquires New Shares in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Purchases 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
UBS Group Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - Defense World
Arvinas (ARVN) Price Target Slashed by UBS but Rating Maintained | ARVN Stock News - GuruFocus
UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating - marketscreener.com
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | - GuruFocus
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | ARVN Stock News - GuruFocus
Dimensional Fund Advisors LP Acquires 186,254 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):